InflaRx N.V. (Nasdaq: IFRX) received a Nasdaq deficiency notice dated March 11, 2026, which was announced on March 13, 2026, after its ordinary shares closed below the $1.00 minimum bid price for 30 consecutive business days. The Nasdaq Listing Rule 5450(a)(1) requires a minimum bid price of $1.00; failure to meet this threshold triggers a deficiency notice and a 180‑day compliance window.
The company has a history of similar compliance issues. In July 2025, InflaRx received a deficiency notice with a deadline of January 7, 2026. It regained compliance on September 11, 2025, after trading above $1.00 for 10 consecutive business days from August 27 to September 10, 2025. The recurrence raises concerns about the stability of the stock price and investor confidence.
As of March 10, 2026, InflaRx’s share price was $0.93, with a market capitalization of roughly $64 million. On March 13, the price was $0.95, still below the Nasdaq threshold. The deficiency notice gives the company until September 7, 2026, to restore the bid price. If it fails, InflaRx may transfer to the Nasdaq Capital Market, which would extend the compliance period to March 8, 2027, but would downgrade its listing tier.
InflaRx has announced a significant restructuring plan that includes a workforce reduction of about 30%. The restructuring is expected to generate a one‑time charge and extend the company’s cash runway to mid‑2027, allowing it to focus resources on the development of its lead drug candidate, izicopan, and the anti‑C5a antibody vilobelimab.
The deficiency notice and the company’s ongoing restructuring signal that InflaRx is under pressure to stabilize its share price while advancing its pipeline. The Nasdaq compliance window provides a deadline for the company to demonstrate that its stock can sustain the $1.00 minimum bid price, a key metric for maintaining investor confidence and liquidity.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.